Download Document

[TO BE PUBLISHED IN THE GAZETTE OF INDIA, EXTRAORDINARY, PART II,
SECTION 3, SUB-SECTION (i)]
GOVERNMENT OF INDIA
MINISTRY OF FINANCE
(DEPARTMENT OF REVENUE)

Notification No. 83 /2017-Customs
New Delhi, the 31
st
October, 2017
G.S.R. (E). - In exercise of the powers conferred by sub-section (1) of section 25 of the
Customs Act, 1962 (52 of 1962), the Central Government, on being satisfied that it is necessary
in the public interest so to do, hereby makes the following further amendments in the
notification of the Government of India, in the Ministry of Finance (Department of Revenue),
No. 16/2017-Customs, dated the 20th April, 2017, published in the Gazette of India,
Extraordinary, Part II, Section 3, Sub-section (i), vide number G.S.R.394 (E), dated the 20th
April, 2017, namely: -
In the said notification, in the Table, after serial number 27 and the entries relating
thereto, the following serial numbers and entries shall be added, namely: -
(1) (2) (3) (4)
“28. Erlotinib
(Tarceva)
The Blue Tree Roche Products
(India) Private Limited
29 Trastuzumab
(Herclon)
The Blue Tree Roche Products
(India) Private Limited
30. Pertuzumab (Perjeta) The Blue Tree Roche Products
(India) Private Limited
31. Transtuzumab
Emtansine
(Kadcyla)
The Blue Tree Roche Products
(India) Private Limited
32. Obinutuzumab
(Gazyva)
The Blue Tree Roche Products
(India) Private Limited
33. Bevacizumab
(Avastin)
The Blue Tree Roche Products
(India) Private Limited
34. Tocilizumab
(Actemra)
Care for Joints Roche Products
(India) Private Limited
35. Mycophenolate
Mofetil
(CellCept)
Aarambh Roche Products
(India) Private Limited
36. Avonex (Interferon
Beta 1A)
Reach UCB India Private Limited

37. Tysabri
(Monoclonal
Antibody
Reach UCB India Private Limited
38. Tecfidera (Di-
methyl Fumarate)
Reach UCB India Private Limited
39. Plegridy Reach UCB India Private Limited

(Peggylated
Interferon Beta 1A)


40. Sorafenib
(Nexavar)
NexCSP (Nexavar Cancer
Survivorship Program)
Bayer Zydus
Pharma Private Limited
41. Sirturo
(Bedaquiline)
Bedaquiline Compassionate
Use Program
Janssen India,
Johnson & Johnson Private
Limited
42. Darzalex
(Daratumumab)
Daratumumab Patient
Assistance Program
Janssen India,
Johnson & Johnson Private
Limited
43. SUTENT - Patients initially pay for 12
strips (value equivalent of 50
mg) and gets assistance of 12
strips free.
- Post purchase of 12 strips
patients receive the drug free
until prescribed by treating
physicians.
-Full subsidy for BPL
patients
Pfizer Products India Private
Limited
44. CRIZALK Patients will pay for 8 bottles
(either 200 mg or 250 mg)
and post that will get the
drug free until prescribed by
treating physician.
- Full subsidy for BPL
patients
Pfizer Products India Private
Limited
45. INLYTA Sutent Patients who
progresses and prescribed
lnlyta as 2nd line pays for 1
strip and gets 1 strip free.
- Patients who progresses on
other 1st line TKI pays for 2
strips and get 1 strip free.
-Ful1subsidy for BPL
patients
Pfizer Products India Private
Limited
46. PALBACE -Patients will pay for 10
cycles and post that will get
free drug support until
prescribed by treating
physicians.
- Full subsidy for BPL
patients
Pfizer Products India Private
Limited




47.




ENBREL
ENLIVEN

-Enbrel 50 mg: 4+2PAP.
Any further repeat purchase
will be given at a further
discounted price




Pfizer Limited

-Enbrel25mg: 8+4 PAP. Any
further repeat purchase will
be given at a further
discounted price

48.

XELJANZ
XELSOURCE
India specific price of Rs.
24000 per bottle (MRP is Rs.
66000 per bottle)

Pfizer Limited
49. GENPTROPIN 5+1 PAP Pfizer Products India Private
Limited

50.

Atgam
For AIIMS Delhi 5+1, KEM
Mumbai 4+1, CMC Vellore
4+1 & Other hospitals 20+4
Pfizer Products India Private
Limited
51. Aromasin PAP 1+1 Pfizer Products India Private
Limited
52. Campto PAP 1+1 Pfizer Products India Private
Limited”.
[F. No. 332/24/2010-TRU (Pt. I)]

(Ruchi Bisht)
Under Secretary to the Government of India

Note: The principal notification No. 16/2017-Customs, dated the 20th April, 2017, published
in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i) vide number
G.S.R.394 (E), dated the 20th April, 2017.